Analysis of the 2017 American Society for Radiation Oncology (ASTRO) Research Portfolio

James B. Yu, Tyler F. Beck, Mitchell Steven Anscher, Andrew M. Baschnagel, Kristy Brock, David J. Carlson, Michael M. Dominello, Randall J. Kimple, Jonathan P. Knisely, Marc S. Mendonca, Omar Y. Mian, Anurag K. Singh, Eduardo G. Moros, Judith C. Keen

Research output: Contribution to journalArticle

Abstract

Purpose: Research in radiation oncology (RO) is imperative to support the discovery of new uses of radiation and improvement of current approaches to radiation delivery and to foster the continued evolution of our field. Therefore, in 2016, the American Society of Radiation Oncology performed an evaluation of research grant funding for RO. Methods and Materials: Members of the Society of Chairs of Academic Radiation Oncology Programs (SCAROP) were asked about funded and unfunded grants that were submitted by their departments between the fiscal years 2014 and 2016. Grants were grouped according to broad categories defined by the 2017 American Society of Radiation Oncology Research Agenda. Additionally, active grants in the National Institutes of Health (NIH) Research Portfolio Online Reporting Tools database were collated using RO faculty names. Results: Overall, there were 816 funded (44%) and 1031 unfunded (56%) SCAROP-reported grants. Total grant funding was over $196 million. The US government funded the plurality (42.2%; 345 of 816) of grants compared with nonprofit and industry funders. Investigators from 10 institutions accounted for >75% of funded grants. Of the funded grants, 43.5% were categorized as “genomic influences and targeted therapies.” The proportion of funded to unfunded grants was highest within the category of “tumor microenvironment, normal tissue effects, and reducing toxicity” (53.4% funded). “New clinical trial design and big data” had the smallest share of SCAROP grant applications and the lowest percent funded (38.3% of grants). NIH grants to RO researchers in 2014 to 2016 accounted for $85 million in funding. From the 31 responding SCAROP institutions, there was a 28% average success rate for RO proposals submitted to the NIH during this period. Conclusions: Though RO researchers from responding institutions were relatively successful in obtaining funding, the overall amount awarded remains small. Continued advocacy on behalf of RO is needed, as well as investment to make research careers more attractive areas for emerging faculty.

Original languageEnglish (US)
Pages (from-to)297-304
Number of pages8
JournalInternational Journal of Radiation Oncology Biology Physics
Volume103
Issue number2
DOIs
StatePublished - Feb 1 2019

Fingerprint

Radiation Oncology
Organized Financing
radiation
Research
National Institutes of Health (U.S.)
seats
health
Research Personnel
Radiation
Tumor Microenvironment
Names
toxicity
Industry

ASJC Scopus subject areas

  • Radiation
  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Analysis of the 2017 American Society for Radiation Oncology (ASTRO) Research Portfolio. / Yu, James B.; Beck, Tyler F.; Anscher, Mitchell Steven; Baschnagel, Andrew M.; Brock, Kristy; Carlson, David J.; Dominello, Michael M.; Kimple, Randall J.; Knisely, Jonathan P.; Mendonca, Marc S.; Mian, Omar Y.; Singh, Anurag K.; Moros, Eduardo G.; Keen, Judith C.

In: International Journal of Radiation Oncology Biology Physics, Vol. 103, No. 2, 01.02.2019, p. 297-304.

Research output: Contribution to journalArticle

Yu, JB, Beck, TF, Anscher, MS, Baschnagel, AM, Brock, K, Carlson, DJ, Dominello, MM, Kimple, RJ, Knisely, JP, Mendonca, MS, Mian, OY, Singh, AK, Moros, EG & Keen, JC 2019, 'Analysis of the 2017 American Society for Radiation Oncology (ASTRO) Research Portfolio', International Journal of Radiation Oncology Biology Physics, vol. 103, no. 2, pp. 297-304. https://doi.org/10.1016/j.ijrobp.2018.07.2056
Yu, James B. ; Beck, Tyler F. ; Anscher, Mitchell Steven ; Baschnagel, Andrew M. ; Brock, Kristy ; Carlson, David J. ; Dominello, Michael M. ; Kimple, Randall J. ; Knisely, Jonathan P. ; Mendonca, Marc S. ; Mian, Omar Y. ; Singh, Anurag K. ; Moros, Eduardo G. ; Keen, Judith C. / Analysis of the 2017 American Society for Radiation Oncology (ASTRO) Research Portfolio. In: International Journal of Radiation Oncology Biology Physics. 2019 ; Vol. 103, No. 2. pp. 297-304.
@article{e4725f3cbad64a6489dc1031af089b3e,
title = "Analysis of the 2017 American Society for Radiation Oncology (ASTRO) Research Portfolio",
abstract = "Purpose: Research in radiation oncology (RO) is imperative to support the discovery of new uses of radiation and improvement of current approaches to radiation delivery and to foster the continued evolution of our field. Therefore, in 2016, the American Society of Radiation Oncology performed an evaluation of research grant funding for RO. Methods and Materials: Members of the Society of Chairs of Academic Radiation Oncology Programs (SCAROP) were asked about funded and unfunded grants that were submitted by their departments between the fiscal years 2014 and 2016. Grants were grouped according to broad categories defined by the 2017 American Society of Radiation Oncology Research Agenda. Additionally, active grants in the National Institutes of Health (NIH) Research Portfolio Online Reporting Tools database were collated using RO faculty names. Results: Overall, there were 816 funded (44{\%}) and 1031 unfunded (56{\%}) SCAROP-reported grants. Total grant funding was over $196 million. The US government funded the plurality (42.2{\%}; 345 of 816) of grants compared with nonprofit and industry funders. Investigators from 10 institutions accounted for >75{\%} of funded grants. Of the funded grants, 43.5{\%} were categorized as “genomic influences and targeted therapies.” The proportion of funded to unfunded grants was highest within the category of “tumor microenvironment, normal tissue effects, and reducing toxicity” (53.4{\%} funded). “New clinical trial design and big data” had the smallest share of SCAROP grant applications and the lowest percent funded (38.3{\%} of grants). NIH grants to RO researchers in 2014 to 2016 accounted for $85 million in funding. From the 31 responding SCAROP institutions, there was a 28{\%} average success rate for RO proposals submitted to the NIH during this period. Conclusions: Though RO researchers from responding institutions were relatively successful in obtaining funding, the overall amount awarded remains small. Continued advocacy on behalf of RO is needed, as well as investment to make research careers more attractive areas for emerging faculty.",
author = "Yu, {James B.} and Beck, {Tyler F.} and Anscher, {Mitchell Steven} and Baschnagel, {Andrew M.} and Kristy Brock and Carlson, {David J.} and Dominello, {Michael M.} and Kimple, {Randall J.} and Knisely, {Jonathan P.} and Mendonca, {Marc S.} and Mian, {Omar Y.} and Singh, {Anurag K.} and Moros, {Eduardo G.} and Keen, {Judith C.}",
year = "2019",
month = "2",
day = "1",
doi = "10.1016/j.ijrobp.2018.07.2056",
language = "English (US)",
volume = "103",
pages = "297--304",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Analysis of the 2017 American Society for Radiation Oncology (ASTRO) Research Portfolio

AU - Yu, James B.

AU - Beck, Tyler F.

AU - Anscher, Mitchell Steven

AU - Baschnagel, Andrew M.

AU - Brock, Kristy

AU - Carlson, David J.

AU - Dominello, Michael M.

AU - Kimple, Randall J.

AU - Knisely, Jonathan P.

AU - Mendonca, Marc S.

AU - Mian, Omar Y.

AU - Singh, Anurag K.

AU - Moros, Eduardo G.

AU - Keen, Judith C.

PY - 2019/2/1

Y1 - 2019/2/1

N2 - Purpose: Research in radiation oncology (RO) is imperative to support the discovery of new uses of radiation and improvement of current approaches to radiation delivery and to foster the continued evolution of our field. Therefore, in 2016, the American Society of Radiation Oncology performed an evaluation of research grant funding for RO. Methods and Materials: Members of the Society of Chairs of Academic Radiation Oncology Programs (SCAROP) were asked about funded and unfunded grants that were submitted by their departments between the fiscal years 2014 and 2016. Grants were grouped according to broad categories defined by the 2017 American Society of Radiation Oncology Research Agenda. Additionally, active grants in the National Institutes of Health (NIH) Research Portfolio Online Reporting Tools database were collated using RO faculty names. Results: Overall, there were 816 funded (44%) and 1031 unfunded (56%) SCAROP-reported grants. Total grant funding was over $196 million. The US government funded the plurality (42.2%; 345 of 816) of grants compared with nonprofit and industry funders. Investigators from 10 institutions accounted for >75% of funded grants. Of the funded grants, 43.5% were categorized as “genomic influences and targeted therapies.” The proportion of funded to unfunded grants was highest within the category of “tumor microenvironment, normal tissue effects, and reducing toxicity” (53.4% funded). “New clinical trial design and big data” had the smallest share of SCAROP grant applications and the lowest percent funded (38.3% of grants). NIH grants to RO researchers in 2014 to 2016 accounted for $85 million in funding. From the 31 responding SCAROP institutions, there was a 28% average success rate for RO proposals submitted to the NIH during this period. Conclusions: Though RO researchers from responding institutions were relatively successful in obtaining funding, the overall amount awarded remains small. Continued advocacy on behalf of RO is needed, as well as investment to make research careers more attractive areas for emerging faculty.

AB - Purpose: Research in radiation oncology (RO) is imperative to support the discovery of new uses of radiation and improvement of current approaches to radiation delivery and to foster the continued evolution of our field. Therefore, in 2016, the American Society of Radiation Oncology performed an evaluation of research grant funding for RO. Methods and Materials: Members of the Society of Chairs of Academic Radiation Oncology Programs (SCAROP) were asked about funded and unfunded grants that were submitted by their departments between the fiscal years 2014 and 2016. Grants were grouped according to broad categories defined by the 2017 American Society of Radiation Oncology Research Agenda. Additionally, active grants in the National Institutes of Health (NIH) Research Portfolio Online Reporting Tools database were collated using RO faculty names. Results: Overall, there were 816 funded (44%) and 1031 unfunded (56%) SCAROP-reported grants. Total grant funding was over $196 million. The US government funded the plurality (42.2%; 345 of 816) of grants compared with nonprofit and industry funders. Investigators from 10 institutions accounted for >75% of funded grants. Of the funded grants, 43.5% were categorized as “genomic influences and targeted therapies.” The proportion of funded to unfunded grants was highest within the category of “tumor microenvironment, normal tissue effects, and reducing toxicity” (53.4% funded). “New clinical trial design and big data” had the smallest share of SCAROP grant applications and the lowest percent funded (38.3% of grants). NIH grants to RO researchers in 2014 to 2016 accounted for $85 million in funding. From the 31 responding SCAROP institutions, there was a 28% average success rate for RO proposals submitted to the NIH during this period. Conclusions: Though RO researchers from responding institutions were relatively successful in obtaining funding, the overall amount awarded remains small. Continued advocacy on behalf of RO is needed, as well as investment to make research careers more attractive areas for emerging faculty.

UR - http://www.scopus.com/inward/record.url?scp=85059567949&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059567949&partnerID=8YFLogxK

U2 - 10.1016/j.ijrobp.2018.07.2056

DO - 10.1016/j.ijrobp.2018.07.2056

M3 - Article

VL - 103

SP - 297

EP - 304

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 2

ER -